Drug intelligence / Profile preview

[11C]-DASB + [18F]-altanserin

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[11C]-DASB + [18F]-altanserin is a combination of two radiolabeled small molecules used as positron emission tomography (PET) tracers for in vivo imaging of the serotonergic system in the brain. - **[11C]-DASB** ([carbon-11]3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile) is a highly selective radiotracer for the serotonin transporter (SERT/5-HTT), allowing quantification of SERT density and distribution in various neuropsychiatric conditions. It binds reversibly and with high specificity to SERT[3][1][7]. - **[18F]-altanserin** ([fluorine-18] altanserin) is a selective antagonist radiotracer for the serotonin 2A receptor (5-HT2A). Labeled with fluorine-18, it enables PET imaging and quantification of 5-HT2A receptor binding potential in cortical and subcortical regions. Both tracers are widely used in research on psychiatric disorders such as depression, Parkinson’s disease with impulse control disorders, and other conditions involving serotonergic dysfunction[1][5][7].

Other names
11C-DASB18F-altanserinDASBaltanserin
02

Targets

HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on [11C]-DASB + [18F]-altanserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]-DASB + [18F]-altanserin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call